Introduction {#Sec1}
============

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype accounting for 15% of breast cancer in women of Caucasian descent^[@CR1]^. It is defined by lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. TNBC is associated with younger age at diagnosis, higher tumor grade, and advanced disease stage and is associated with an increased risk of recurrence and worse survival relative to other subtypes^[@CR2]^. The absence of expression of the three receptors strongly reduces targeted treatment options and as such, there is an urgent need to identify novel targets for treatment^[@CR3],[@CR4]^ or improve early detection.

Aberrant DNA methylation is reported in tumor tissue of many cancers including breast cancer^[@CR5],[@CR6]^. Similar alterations are detectable in peripheral blood leukocyte (PBL) DNA from cancer patients implying that blood-based DNA methylation markers may be of clinical value for early detection and risk stratification^[@CR7],[@CR8]^. In breast cancer, several global and gene-specific DNA methylation studies have been performed on PBL-derived DNA^[@CR9]^. Global DNA methylation measures have yielded inconsistent findings^[@CR9],[@CR10]^. There is evidence that local hypermethylation at the *BRCA1*^[@CR11],[@CR12]^ gene promoter and hypermethylation at the *ATM* gene body^[@CR13],[@CR14]^ in PBL DNA is more frequent in breast cancer cases compared with controls. Hypermethylation of the *BRCA1* promoter in PBL DNA was also associated with a greater risk of TNBC compared to other breast subtypes, indicating its application as a novel methylation biomarker of increased TNBC susceptibility^[@CR15]^. In another study hypermethylation of *DOK7* in whole blood DNA was proposed as a powerful epigenetic blood-based biomarker for TNBC^[@CR16]^.

Using a retrospective study design, we recently identified and validated a region within the long noncoding RNA 299 (*LINC00299*) gene that showed a higher methylation (3% in the discovery set and 2% in the validation set) in PBL DNA from TNBC patients compared with healthy controls^[@CR17]^, suggesting that this may be a biomarker for TNBC. The hypermethylated region is located in a putative regulatory region of the *LINC00299* gene, the function of which is unknown.

In the present study, we tested whether *LINC00299* methylation level is associated with TNBC using a prospective study design. Methylation was measured in PBL DNA from 154 TNBC cases and 159 matched controls in a nested case--control study within the prospective Generations Study (GS) cohort using droplet digital PCR (ddPCR).

Results {#Sec2}
=======

Methylation at cg06588802 in *LINC00299* was measured in peripheral blood DNA of 154 TNBC cases and 159 matched controls from the study. Selected characteristics of the study participants are shown in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of triple negative breast cancer cases and controls \[matched on year of study entry, age at entry, days blood was in the post before processing, and cancer-free years in the study (time at risk)\].CharacteristicCases n (%)Controls n (%)Total^a^154159Age at study entry \[mean (range), years\]52.1 (24--80)52.1 (22--81)Year of study entry2004--20102004--2009Age at blood draw \[mean (range), years\]52.1 (24--80)52.2 (22--81)Age at diagnosis date \[mean (range), years\]56.7 (26--87)--Blood draw to diagnosis \[mean (range), years\]4.6 (0--10)--**Days blood in post**0--1116 (75.3)120 (75.5)211 (7.1)11 (6.9)3+27 (17.5)28 (17.6)**Smoking status**Never94 (61.0)94 (59.1)Ex-smoker51 (33.1)53 (33.3)Current9 (5.8)12 (7.6)*TNBC* triple negative breast cancer.^a^Including twelve participants with prior cancer (that is not breast cancer).

Mean methylation levels were higher in TNBC cases compared with controls. However, this difference did not reach statistical significance (*P* = 0.062). In analyses stratified by age, women in the lowest tertile of age at diagnosis (26--52) and age at blood draw (22--46) had statistically significant higher mean methylation levels in cases compared with controls \[*P* = 0.0025 and *P* = 0.0010, respectively; (post-hoc power \> 90% in both instances); Table [2](#Tab2){ref-type="table"}\]. No significant differences between cases and controls were detected for women in the second and third age tertiles.Table 2Difference in methylation levels for triple negative breast cancer cases versus controls: matched analysis (analysis of variance), stratified by age (tertiles).CasesControlsMatched analysis^a^StratanMean methylation level (SD)nMean methylation level (SD)*P* value1540.430 (0.051)1590.420 (0.051)0.062**Age at diagnosis**26--52500.453 (0.036)510.423 (0.043)0.002553--62530.433 (0.044)560.429 (0.053)0.7663+510.404 (0.059)520.405 (0.056)0.94Heterogeneity (*df* = 3)^b^0.025**Age at blood draw**22--46480.454 (0.036)520.427 (0.042)0.001047--58590.429 (0.049)580.422 (0.055)0.4659+470.406 (0.056)490.410 (0.057)0.54Heterogeneity (*df* = 3)^b^0.0079*SD* standard deviation, *df* degrees of freedom.^a^Controls matched on year of study entry, age at study entry, days blood in post before processing, and cancer-free years (time at risk).^b^Heterogeneity test: tests if the difference between cases and controls varies by age.

Analysis by quartile revealed no association between methylation levels at cg0658802 in *LINC00299* and TNBC risk, adjusted for smoking status (Table [3](#Tab3){ref-type="table"}). Similar results were obtained after exclusion of twelve study participants with prior cancer and their matched case or control (Q2: OR 0.64, 95% CI 0.29--1.41; Q3: OR 1.58, 95% CI 0.78--3.20; Q4: OR 1.08, 95% CI 0.51--2.31).Table 3Odds ratio of triple negative breast cancer in relation to methylation levels at cg06588802 in *LINC00299*, all ages.Methylation levelQuartile (Q)MeanCases nControls nOR^a^95% CI*P* valueTotal^b^154159Q1 (0.289--0.388)0.35434411.00BaselineQ2 (0.389--0.420)0.40626390.800.37--1.710.56Q3 (0.421--0.461)0.44151401.510.77--2.980.23Q4 (0.462--0.558)0.48643391.270.61--2.630.53Trend (across quartiles)0.14Trend (across methylation ratio)0.082*OR* odds ratio, *CI* confidence interval.^a^Conditional matched analysis \[year of entry to study, age at entry, days blood in post before processing, and cancer-free years (time at risk)\], adjusted for smoking status.^b^Including twelve participants with prior cancer (that is not breast cancer).

Discussion {#Sec3}
==========

This is the first study to investigate an association between TNBC and gene-specific methylation in prediagnostic blood samples of TNBC cases and age-matched controls using ddPCR as a highly quantitative method. We found no evidence for association of *LINC00299* methylation levels with TNBC overall. However, in analysis stratified by age at diagnosis and age at blood draw, higher methylation levels were observed in the youngest age subgroup of TNBC cases compared with controls, but not in the older age subgroups. These findings imply that *LINC00299* methylation level may be useful as a biomarker for TNBC in young women, which has not been examined previously. The different results obtained in the age subgroups might be explained by differences in molecular features of TNBC between younger and older women. One study for example showed that women younger than 50 years at the time of diagnosis had a higher prevalence of TNBC of the basal-like molecular subtype and a lower prevalence of the HER2-enriched subtype compared with those who were older at the time of diagnosis (≥ 65 years)^[@CR18]^. However, we did not have this level of molecular subtyping in our cases to be able to examine this further. Also younger women were more likely to develop TNBCs with poor prognostic parameters, such as higher histological grade, higher number of positive lymph nodes, larger tumor size, higher proliferation rate, and higher TNM stage^[@CR2]^. It is also reported that *BRCA1* promoter methylation in peripheral blood increases the risk of having early onset breast cancer^[@CR19]^. Furthermore, it was reported that younger TNBC patients (\< 40 years) had a worse survival than their older (\> 50 years) counterparts^[@CR20],[@CR21]^.

A statistically significant methylation difference between TNBC cases and controls was reported in our initial study^[@CR17]^. In the present study, however, this difference did not reach statistical significance. The main difference between the studies is that in the present study blood samples were taken from women before the diagnosis of TNBC, excluding the possibility that methylation variability in PBL DNA was modified by the presence of clinical cancer or treatment of these patients. In the previous study, blood samples were drawn at the time of TNBC diagnosis and tumors can directly influence the host immune system by releasing factors that modulate functions of leukocytes or induce apoptosis of these cells^[@CR22]^. This may lead to changes in PBL DNA methylation levels. Other explanations may be differences in study size, population, and matching criteria (matched on age at study entry ± 5-years, year of study entry, days blood in post before processing, and cancer-free years (time at risk) versus matched on age at diagnosis for cases and interview for controls ± 1 year).

The CpG site cg06588802 is located at the chromosomal region 2p25.1 within the *LINC00299* gene. LncRNAs have recently emerged as important regulators of gene expression in various cell types. They control the development and function of specific immune cells through a variety of mechanisms^[@CR23]^. The hypermethylated region in the *LINC00299* gene is evolutionarily conserved and overlaps with several enhancer regions suggesting its possible regulatory functions. Data of the three-dimensional chromatin structure showed physical interactions between the genomic region of *LINC00299* and the *ID2* gene promoter, a protein with important immune functions^[@CR24]^. This suggests a potential function of *LINC00299* in the regulation of specific immune cells, which needs to be elucidated in functional studies. Further, based on expression data from The Cancer Genome Atlas, ER- and PR-negative breast cancer patients with high *LINC00299* expression had a better survival than those with low expression^[@CR17]^.

In conclusion, though no association between *LINC00299* methylation and TNBC overall was observed, our findings suggest that *LINC00299* hypermethylation in prediagnostic PBL DNA may be associated with TNBC in young women. If replicated in larger studies, *LINC00299* hypermethylation may be of clinical value as a biomarker for early-detection of TNBC in young women.

Methods {#Sec4}
=======

Study population {#Sec5}
----------------

Study participants were selected from the GS, a long-term prospective breast cancer cohort study focused on potential etiological factors for breast cancer in women in the UK, with blood samples collected at recruitment^[@CR25]^. The study has been approved, under the procedures for national medical research studies, by the South-East Multi-Centre Research Ethics Committee.

The present study selected 161 TNBC cases and matched controls of Caucasian ethnicity for methylation assay. Cases were women who were diagnosed with a first triple-negative invasive or in situ primary breast cancer after study entry. Controls were women with no diagnosis of breast cancer. Individual controls were selected for each case, matched on age (5-year categories), year of study entry (≤ 2005, 2006, 2007, ≥ 2008), the number of days the blood had been in the post (0--1, 2, ≥ 3), and cancer-free years (time at risk). After updating data files prior to statistical analysis, four cases were subsequently found to have provided blood samples after diagnosis of TNBC and therefore were excluded from the analysis. Further, three cases and two controls had missing methylation data. Hence, nine women (two cases/seven controls) were no longer in a matched pair; these nine women were re-allocated to a matched set with the same age, study entry year, days blood in post grouping, but different cancer free time (thus allowing the inclusion of these women in the matched analysis). In total, the study included 154 cases (diagnosed with a first triple-negative invasive (n = 149) or in situ (n = 5) primary breast cancer after study entry) and 159 controls.

Methylation analysis {#Sec6}
--------------------

DNA samples were extracted from buffy coats using DNA Blood Mini Kits (Qiagen, Hilden, Germany). Two hundred ng of DNA were bisulfite-converted using EpiTect Fast 96 Bisulfite Conversion Kit according to the manufacturer\'s protocol (Qiagen). DNA methylation analysis at cg06588802 in *LINC00299* was performed using MethyLight droplet digital PCR (ddPCR) as previously described^[@CR17]^. In brief, methylation ratios were defined by locus-specific primers using TaqMan assays. The C-LESS-C1 assay was used as internal control for normalization. Each reaction was performed in a final volume of 20 μl containing 10 μl ddPCR Supermix for Probes (No dUTP) (Bio-Rad, Hercules, CA, USA), 900 nM forward and reverse primers, 250 nM probe, 2 µl bisulfite converted DNA template, and 6 µl nuclease-free double distilled H~2~O. All ddPCR steps were performed according to the manufacturer's protocols (Bio-Rad). Cycling was at 95 °C for 10 min, followed by 40 cycles of 94 °C for 30 s and 59 °C for 60 s, and a final step at 98 °C for 10 min. To ensure equal conditions for cases and controls during all ddPCR steps, case--control pairs were allocated on the same cartridge of the assay to minimize batch effects. Duplicates and fully methylated and unmethylated controls were used on each ddPCR plate for quality control.

Statistical analysis {#Sec7}
--------------------

Analysis of variance was used to assess the difference in methylation levels between TNBC cases and matched controls (i.e. with implicit adjustment for the matching factors).

Stratified analysis (tertiles) was performed by age at diagnosis (for controls this was the matched case's age at diagnosis) and age at blood draw.

For the association between methylation level and TNBC risk, conditional logistic regression was used to calculate odd ratios (ORs) and 95% confidence intervals (CIs). We adjusted for smoking status (at recruitment: never, ex-smoker, current) as *LINC00299* methylation level is changed in response to cigarette smoking^[@CR26]^.

All *P* values were two-sided, with a *P* value of 0.05 considered statistically significant. Stata/IC version 14.2 was used for all analyses^[@CR27]^.

Ethical approval {#Sec8}
----------------

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study has been approved by the South-East Multi-Centre Research Ethics Committee.

Informed consent {#Sec9}
----------------

Informed consent was obtained from all individual participants included in the study.
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